DONOR SPECIFIC TRANSFUSION/CYCLOSPORINE A

供体特异性输血/环孢菌素 A

• 批准号: 6244009
• 负责人: ARNOLD G DIETHELM
• 金额: $ 2.46万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-02-10 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6244009
• 关键词: artificial immunosuppression; blood transfusion; bone marrow transplantation; clinical research; clinical trials; cyclosporines; haploidy; human subject; human therapy evaluation; immune tolerance /unresponsiveness; kidney transplantation; postmortem; tissue donors; transplant rejection

Specific aims of the Cooperative Clinical Trials in Transplantation are to induce donor specific unresponsiveness in living related kidney transplant patients, as well as to determine the safety and benefit in terms of lessened rejection and improved graft survival from the administration of donor bone marrow cells to recipients of cadaveric renal transplants. An improved understanding of methods in inducing tolerance in clinical transplantation will allow increased success rates which will be of direct benefit to many patients with end stage organ failure. The induction of allogenieic tolerance and the basic principles involved in tolerance induction may theoretically be of benefit also to those patients suffering from autoimmune disease.

移植中合作临床试验的具体目的是 诱导捐助者在与活着的肾脏方面的特定反应症 移植患者，以及确定的安全性和利益 拒绝和改善的移植物生存的条款 施用供体骨髓细胞对尸体的接受者 肾移植。 对诱导临床耐受性的方法的提高理解 移植将允许提高成功率，这将是 对许多终阶段器官衰竭患者的直接益处。 这 同种异体耐受性和涉及的基本原则的诱导 从理论上讲，在宽容诱导方面也可能有益于那些 患有自身免疫性疾病的患者。